These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 30588017)

  • 41. Assessment of early response biomarkers in relation to long-term survival in patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy plus bevacizumab: Results from the Phase II PROMIX trial.
    Kimbung S; Markholm I; Bjöhle J; Lekberg T; von Wachenfeldt A; Azavedo E; Saracco A; Hellström M; Veerla S; Paquet E; Bendahl PO; Fernö M; Bergh J; Loman N; Hatschek T; Hedenfalk I;
    Int J Cancer; 2018 Feb; 142(3):618-628. PubMed ID: 28940389
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Neoadjuvant Therapy for HER2-positive Breast Cancer.
    Wuerstlein R; Harbeck N
    Rev Recent Clin Trials; 2017; 12(2):81-92. PubMed ID: 28164759
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Neoadjuvant dual HER2-targeted therapy with lapatinib and trastuzumab improves pathologic complete response in patients with early stage HER2-positive breast cancer: a meta-analysis of randomized prospective clinical trials.
    Hicks M; Macrae ER; Abdel-Rasoul M; Layman R; Friedman S; Querry J; Lustberg M; Ramaswamy B; Mrozek E; Shapiro C; Wesolowski R
    Oncologist; 2015 Apr; 20(4):337-43. PubMed ID: 25732265
    [TBL] [Abstract][Full Text] [Related]  

  • 44. TBCRC 002: a phase II, randomized, open-label trial of preoperative letrozole with or without bevacizumab in postmenopausal women with newly diagnosed stage 2/3 hormone receptor-positive and HER2-negative breast cancer.
    Vaklavas C; Roberts BS; Varley KE; Lin NU; Liu MC; Rugo HS; Puhalla S; Nanda R; Storniolo AM; Carey LA; Saleh MN; Li Y; Delossantos JF; Grizzle WE; LoBuglio AF; Myers RM; Forero-Torres A;
    Breast Cancer Res; 2020 Feb; 22(1):22. PubMed ID: 32070401
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Survival benefit of neoadjuvant chemotherapy for resectable breast cancer: A meta-analysis.
    Chen Y; Shi XE; Tian JH; Yang XJ; Wang YF; Yang KH
    Medicine (Baltimore); 2018 May; 97(20):e10634. PubMed ID: 29768327
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Bevacizumab plus neoadjuvant chemotherapy in patients with HER2-negative inflammatory breast cancer (BEVERLY-1): a multicentre, single-arm, phase 2 study.
    Bertucci F; Fekih M; Autret A; Petit T; Dalenc F; Levy C; Romieu G; Bonneterre J; Ferrero JM; Kerbrat P; Soulie P; Mouret-Reynier MA; Bachelot T; Lerebours F; Eymard JC; Deblock M; Lortholary A; Hardy-Bessard AC; Barthelemy P; Bonnefoi H; Charafe-Jauffret E; Bidard FC; Viens P; Lemonnier J; Pierga JY
    Lancet Oncol; 2016 May; 17(5):600-11. PubMed ID: 27032301
    [TBL] [Abstract][Full Text] [Related]  

  • 47. De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET.
    Harbeck N; Gluz O; Christgen M; Kates RE; Braun M; Küemmel S; Schumacher C; Potenberg J; Kraemer S; Kleine-Tebbe A; Augustin D; Aktas B; Forstbauer H; Tio J; von Schumann R; Liedtke C; Grischke EM; Schumacher J; Wuerstlein R; Kreipe HH; Nitz UA
    J Clin Oncol; 2017 Sep; 35(26):3046-3054. PubMed ID: 28682681
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer.
    von Minckwitz G; Eidtmann H; Rezai M; Fasching PA; Tesch H; Eggemann H; Schrader I; Kittel K; Hanusch C; Kreienberg R; Solbach C; Gerber B; Jackisch C; Kunz G; Blohmer JU; Huober J; Hauschild M; Fehm T; Müller BM; Denkert C; Loibl S; Nekljudova V; Untch M; ;
    N Engl J Med; 2012 Jan; 366(4):299-309. PubMed ID: 22276820
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Impact of hormone receptor status on the efficacy of HER2-targeted treatment.
    Zhao B; Zhao H; Zhao J
    Endocr Relat Cancer; 2018 Jun; 25(6):687-697. PubMed ID: 29739815
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Association between Pathological Complete Response and Outcome Following Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer Patients.
    Luangdilok S; Samarnthai N; Korphaisarn K
    J Breast Cancer; 2014 Dec; 17(4):376-85. PubMed ID: 25548587
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Survival outcomes of neoadjuvant versus adjuvant chemotherapy in triple-negative breast cancer: a meta-analysis of 36,480 cases.
    Xia LY; Hu QL; Zhang J; Xu WY; Li XS
    World J Surg Oncol; 2020 Jun; 18(1):129. PubMed ID: 32539858
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes.
    Masuda H; Brewer TM; Liu DD; Iwamoto T; Shen Y; Hsu L; Willey JS; Gonzalez-Angulo AM; Chavez-MacGregor M; Fouad TM; Woodward WA; Reuben JM; Valero V; Alvarez RH; Hortobagyi GN; Ueno NT
    Ann Oncol; 2014 Feb; 25(2):384-91. PubMed ID: 24351399
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy and Safety of Bevacizumab Combined with Chemotherapy for Managing Metastatic Breast Cancer: A Meta-Analysis of Randomized Controlled Trials.
    Li Q; Yan H; Zhao P; Yang Y; Cao B
    Sci Rep; 2015 Oct; 5():15746. PubMed ID: 26503902
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Outcomes and prognoses of patients with ovarian cancer using bevacizumab: 6-year experience in a tertiary care hospital of northern Taiwan.
    Chen WC; Qiu JT; Lai CH; Huang HJ; Lin CT; Chen MY; Chou HH; Huang KG; Chang TC
    PLoS One; 2017; 12(5):e0175703. PubMed ID: 28467466
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2010; 10(23):1-57. PubMed ID: 23074401
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Dose-dense chemotherapy in nonmetastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials.
    Bonilla L; Ben-Aharon I; Vidal L; Gafter-Gvili A; Leibovici L; Stemmer SM
    J Natl Cancer Inst; 2010 Dec; 102(24):1845-54. PubMed ID: 21098761
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Impact of clinicopathological characteristics on the efficacy of neoadjuvant therapy in patients with human epidermal growth factor receptor-2-positive breast cancer.
    Zhao B; Zhao H
    Int J Cancer; 2018 Feb; 142(4):844-853. PubMed ID: 29023765
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Use of [(18)F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [(18)F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial.
    Coudert B; Pierga JY; Mouret-Reynier MA; Kerrou K; Ferrero JM; Petit T; Kerbrat P; Dupré PF; Bachelot T; Gabelle P; Giard S; Coeffic D; Bougnoux P; Prevost JB; Paintaud G; Thibault G; Hernandez J; Coudert M; Arnould L; Berriolo-Riedinger A
    Lancet Oncol; 2014 Dec; 15(13):1493-1502. PubMed ID: 25456368
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical tumor stage is the most important predictor of pathological complete response rate after neoadjuvant chemotherapy in breast cancer patients.
    Goorts B; van Nijnatten TJ; de Munck L; Moossdorff M; Heuts EM; de Boer M; Lobbes MB; Smidt ML
    Breast Cancer Res Treat; 2017 May; 163(1):83-91. PubMed ID: 28205044
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial.
    von Minckwitz G; Puglisi F; Cortes J; Vrdoljak E; Marschner N; Zielinski C; Villanueva C; Romieu G; Lang I; Ciruelos E; De Laurentiis M; Veyret C; de Ducla S; Freudensprung U; Srock S; Gligorov J
    Lancet Oncol; 2014 Oct; 15(11):1269-78. PubMed ID: 25273342
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.